ASXL2 Inhibitors
Chemical inhibitors of ASXL2 can exert their effects through various mechanisms impacting the protein's function. Proteasome inhibitors such as MG132, PS-341 (Bortezomib), Lactacystin, and Epoxomicin disrupt the ubiquitin-proteasome system. This system plays a pivotal role in the degradation of proteins, and its inhibition can lead to the accumulation of polyubiquitinated proteins. Such an accumulation could overwhelm the deubiquitinating machinery that ASXL2 is associated with, which is essential for the regulatory functions of ASXL2. By inhibiting the proteasome, these chemicals can indirectly affect ASXL2's role in the cell, particularly in the regulation of chromatin remodeling and gene expression, by altering the turnover of proteins in the pathways in which ASXL2 is involved.
Other chemicals target the ubiquitination process more directly. MLN4924 inhibits the NEDD8-activating enzyme, which is essential for the neddylation that modulates the activity of cullin-RING E3 ubiquitin ligases. This can indirectly affect ASXL2 function by influencing proteins that regulate ASXL2's chromatin targets. PYR-41, an inhibitor of the ubiquitin-activating enzyme E1, and VLX1570, a deubiquitinase inhibitor, can impair ubiquitin-related processes and the deubiquitination control of protein turnover, respectively. These processes are essential for the proper function of ASXL2's regulatory roles. Similarly, P5091 and HBX41108 inhibit specific deubiquitinases (USP7 and USP8), while IU1 targets USP14, each potentially altering the ubiquitin-mediated signaling pathways necessary for ASXL2's function. NSC697923 disrupts UBE2N, which plays a role in ubiquitin conjugation, and WP1130, another deubiquitinase inhibitor, leads to decreased deubiquitinating activity. By affecting the ubiquitin system, these inhibitors can alter the stability and regulatory mechanisms of proteins involved in the pathways regulated by ASXL2, such as histone modification and gene expression control, thereby inhibiting ASXL2 function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to increased levels of ubiquitinated proteins, potentially leading to the functional inhibition of ASXL2 by overwhelming its associated deubiquitinating machinery, which is essential for its regulatory functions. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
PS-341, also known as Bortezomib, is another proteasome inhibitor that can indirectly inhibit ASXL2 by disrupting proteasomal degradation pathways that ASXL2 is involved in, thus affecting its function in the cell. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome, which could lead to the accumulation of polyubiquitinated proteins and indirect inhibition of ASXL2 by affecting the ubiquitin-proteasome system that regulates its stability and function. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. By inhibiting the proteasome, it can affect the turnover of cellular proteins, including those involved in the pathways regulated by ASXL2, thereby indirectly affecting its functional role. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 inhibits NEDD8-activating enzyme, which is critical for the neddylation process that modulates the activity of cullin-RING E3 ubiquitin ligases. Since ASXL2 is involved in chromatin remodeling and gene expression, disrupting this process can indirectly inhibit the function of ASXL2 by affecting the proteins that regulate ASXL2's chromatin targets. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41 is a ubiquitin-activating enzyme E1 inhibitor. By preventing ubiquitin activation, it can indirectly inhibit ASXL2 function by disrupting ubiquitin-related processes that ASXL2 may depend on for modulating gene expression. | ||||||
P005091 | 882257-11-6 | sc-478535 | 10 mg | $155.00 | ||
P5091 is an inhibitor of ubiquitin-specific protease 7 (USP7), which might interact with ASXL2. By inhibiting USP7, it can indirectly affect ASXL2's associated complexes involved in epigenetic regulation and thus inhibit ASXL2 function. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
IU1 is a specific inhibitor of the deubiquitinase USP14. By inhibiting USP14, it could indirectly inhibit ASXL2 function by affecting the ubiquitin-proteasome system and thus influencing the degradation or stability of proteins that regulate ASXL2 activity. | ||||||
NSC697923 | 343351-67-7 | sc-391107 sc-391107A | 1 mg 5 mg | $15.00 $51.00 | 3 | |
NSC697923 is a UBE2N (ubiquitin-conjugating enzyme E2N) inhibitor. By inhibiting UBE2N, it can impair the ubiquitin conjugation process, potentially leading to a functional inhibition of ASXL2 by affecting the ubiquitination status of proteins involved in ASXL2 pathways. | ||||||
WP1130 | 856243-80-6 | sc-364650 sc-364650A | 10 mg 50 mg | $480.00 $1455.00 | 1 | |
WP1130 is a deubiquitinase inhibitor that can lead to decreased deubiquitinating activity. This can indirectly inhibit ASXL2 by affecting the ubiquitin-mediated regulatory mechanisms that ASXL2 is involved in, such as histone modification and gene expression control. | ||||||